ArticleNature2020
The repertoire of mutational signatures in human cancer.
Erratum issued Registry-linked trialAbstract read
In one paragraph
Article in Nature, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT06680791 (Molecular Classification in Relation to Prevention of Endometrial Cancer Recurrence and Lifestyle Factors), which is not on this map. Cited by 2,231 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
2,231citing papers in PubMed, 3 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Molecular Classification in Relation to Prevention of Endometrial Cancer Recurrence and Lifestyle Factors
Who cites it
2,231 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- The Addition of Concurrent Immune Checkpoint Inhibitors for Chemoradiotherapy With Consolidative Immune Checkpoint Inhibitors in Unresectable Cancers: A Systematic Review and Meta-Analysis.International journal of cancer · 2026Pooled it
- Equity and Cancer Survival Among Veterans Health Administration Patients: A Systematic Review and Meta-Analysis.JAMA network open · 2026Pooled it
- Genome-wide meta-analysis across East Asian and European populations provides insights into the molecular basis of lung cancer.Genome medicine · 2026Pooled it
- Mutational Signature-Based Biomarker for Phase II Trial of Olaparib Maintenance in Advanced High-Grade Ovarian Cancer.Cancer science · 2026Trial
- A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Trial
- Cadmium inhibits hSMUG1-mediated uracil excision: quantitative analysis and mitigation byJournal of enzyme inhibition and medicinal chemistry · 2026Article
- Sequence effects on mutation rates investigated in whole-genome sequenced UK Biobank participants.G3 (Bethesda, Md.) · 2026Article
- α7 integrin co-regulates chromatin accessibility and gene expression in HPV-negative head and neck cancer.Signal transduction and targeted therapy · 2026Article
- Rapid Whole Genome Sequencing Enhances Pediatric Cancer Diagnosis.Nature communications · 2026Observational
- Comprehensive Genomic Analysis of Normal and Cancer Cells Elucidates the Elevated Mutational Burden in Cancer.Cancer research · 2026Article
- Whole-Genome Deep Learning Predicts Chemotherapy Response in Colorectal Cancer.Biochemical genetics · 2026Article
- Different primary thyroid B-cell lymphomas show overlapping mutation profiles, suggesting involvement of a common pathogenic process.Haematologica · 2026Article
- Targeting the DNA Damage Response in Cancer.MedComm · 2026Review
- Prevalence of High Programmed Death-Ligand 1 Expression in Pulmonary Sarcomatoid Carcinoma: A Systematic Review and Meta-Analysis.JTO clinical and research reports · 2026Review
- Tumour-agnostic immunotherapy: aligning biological rationale, biomarker precision, and real-world implementation.EClinicalMedicine · 2026Review
- Lipid metabolic reprogramming of macrophage by host APOBEC3 deficiency enhances anti-tumor immunity.British journal of cancer · 2026Article
- Origins and timing of somatic variants in the brain.Current opinion in genetics & development · 2026Review
- Cancer treatment alters mutant selection in normal esophagus.Nature genetics · 2026Article
- Unraveling the lexicon of complex mutational phenomena in human cancers.Nature cancer · 2026Review
- The rate and spectrum of germline mutations in chicken from a commercial pedigree line.Genetics, selection, evolution : GSE · 2026Article
2,171 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Erratum issued
Authors and funding
23 authors.
Ludmil B Alexandrov *Department of Cellular and Molecular Medicine, Department of Bioengineering, Moores Cancer Center, University of California, San Diego, CA, USA.
Jaegil Kim *Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Nicholas J HaradhvalaBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Mi Ni HuangProgramme in Cancer & Stem Cell Biology, Duke-NUS Medical School, Singapore, Singapore.
Alvin Wei Tian NgProgramme in Cancer & Stem Cell Biology, Duke-NUS Medical School, Singapore, Singapore.
Yang WuProgramme in Cancer & Stem Cell Biology, Duke-NUS Medical School, Singapore, Singapore.
Arnoud BootProgramme in Cancer & Stem Cell Biology, Duke-NUS Medical School, Singapore, Singapore.
Kyle R CovingtonHuman Genome Sequencing Center, Baylor College of Medicine, Houston, TX, USA.
Dmitry A GordeninGenome Integrity and Structural Biology Laboratory, National Institute of Environmental Health Sciences (NIEHS), Durham, NC, USA.
Erik N BergstromDepartment of Cellular and Molecular Medicine, Department of Bioengineering, Moores Cancer Center, University of California, San Diego, CA, USA.
S M Ashiqul IslamDepartment of Cellular and Molecular Medicine, Department of Bioengineering, Moores Cancer Center, University of California, San Diego, CA, USA.
Nuria Lopez-BigasInstitute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain.
Leszek J KlimczakIntegrative Bioinformatics Support Group, National Institute of Environmental Health Sciences (NIEHS), Durham, NC, USA.
John R McPhersonProgramme in Cancer & Stem Cell Biology, Duke-NUS Medical School, Singapore, Singapore.
Sandro MorganellaWellcome Sanger Institute, Hinxton, UK.
Radhakrishnan SabarinathanResearch Program on Biomedical Informatics, Universitat Pompeu Fabra, Barcelona, Spain.
David A WheelerHuman Genome Sequencing Center, Baylor College of Medicine, Houston, TX, USA.
Ville MustonenDepartment of Computer Science, University of Helsinki, Helsinki, Finland.
PCAWG Mutational Signatures Working Group
Gad Getz *Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Steven G Rozen *Programme in Cancer & Stem Cell Biology, Duke-NUS Medical School, Singapore, Singapore. steverozen@gmail.com.
Michael R Stratton *Wellcome Sanger Institute, Hinxton, UK. mrs@sanger.ac.uk.
PCAWG Consortium
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8MVIRAL MALIGNANCYP30CA023100 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Jesse Nodora · 1985 to 2026
$124.9MGenome-wide hypermutation and structural instabilityZIAES103266 · NIEHS · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · PI GORDENIN, DMITRY · 2015 to 2025
$18.0MProteomicsP01CA206978 · NCI · DANA-FARBER CANCER INST · PI WU, CATHERINE JU-YING · 2016 to 2025
$17.0MThe Cancer Genome Atlas Data Analysis CenterU24CA143845 · NCI · BROAD INSTITUTE, INC. · PI CHIN, LYNDA, GETZ, GAD A · 2009 to 2016
$16.0MMOLECULAR BIOPHYSICS TRAINING GRANTT32GM008313 · NIGMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI MURTHY, VENKATESH N · 1989 to 2023
$14.6MThe BCM Tumor Genome Characterization CenterU24CA143843 · NCI · BAYLOR COLLEGE OF MEDICINE · PI GIBBS, RICHARD A, WHEELER, DAVID ANDREW · 2009 to 2013
$9.5MGlobal Infrastructure for Collaborative High-throughput Cancer Genomics AnalysisU24CA210999 · NCI · BROAD INSTITUTE, INC. · PI GETZ, GAD A · 2016 to 2020
$4.7MEuropean Research CouncilNCI NIH HHS P01 CA206978NCI NIH HHS P30 CA016672NCI NIH HHS P30 CA023100NCI NIH HHS U24 CA143843NCI NIH HHS U24 CA143845NCI NIH HHS U24 CA210999NIGMS NIH HHS T32 GM008313Wellcome TrustWellcome Trust 206194
Abstract
Somatic mutations in cancer genomes are caused by multiple mutational processes, each of which generates a characteristic mutational signature
Indexed as
Age FactorsBase SequenceExomeGenome, HumanHumansMutationNeoplasmsSequence Analysis, DNA
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
NCT06680791ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.